Fig. 5

Regulating effect of interaction between BGC-823 cells and GC-MSCs on tumor angiogenesis. (A) RT-PCR analysis of VEGF, MIP-2, TGF-β1, IL-6, and IL-8 expression in GC-MSCs, GCN-MSCs, or BM-MSCs. (B) RT-PCR analysis of VEGF, MIP-2, TGF-β1, IL-6, and IL-8 expression in GC-MSCs, GCN-MSCs, or BM-MSCs after exposed to 10 % BGC-823-CM for 3 days. (C) RT-PCR analysis of VEGF, MIP-2, TGF-β1, IL-6, and IL-8 expression in BGC-823 cells after treated with 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs for 3 days. (D) Representative photographs of HUVECs seeded on Matrigel for 8 hrs in culture medium (upper left) and in the presence of 10 % CM from GC-MSCs (upper right), BGC-823 cells (lower left), or co-cultured BGC-823 cells and GC-MSCs (lower right) (×100). (E) Luminex assay of VEGF, IL-6, and IL-8 secretion in the supernatant of GC-MSCs, GCN-MSCs, or BM-MSCs with 10 % BGC-823-CM treatment for 3 days. (F) Luminex assay of VEGF, IL-6, and IL-8 secretion in the supernatant of BGC-823 cells after exposed to 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs for 3 days. *P < 0.05, **P < 0.01: compared with the control group; ^# P < 0.05: compared with the GC-MSC-CM treated group